Letter to the Editor: Can the seasonal influenza vaccine for 2019/2020 have cross reactivity with some of the SARS-CoV-2 proteins?
Main Authors: | Milad Zandi, Emad Behboudi, Saber Soltani |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | International Journal of Infectious Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221006111 |
Similar Items
-
New mutations causing the 2019 novel Coronavirus (2019-nCoV) epidemic: letter to the editor
by: Emad Behboudi, et al.
Published: (2020-10-01) -
New mutations causing the 2019 novel Coronavirus (2019-nCoV) epidemic: letter to the editor
by: Emad Behboudi, et al.
Published: (2020-05-01) -
Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2)
by: Azadeh Haghi Navand, et al.
Published: (2020-01-01) -
Are we still afraid of influenza during the Sars-Cov2 pandemic? - epidemiological analysis of influenza morbidity and vaccination in the 2019/2020 season
by: Kinga Ruszel, et al.
Published: (2020-07-01) -
Importance of nanotechnology in COVID-19 pandemic: letter to the editor
by: Emad Behboudi, et al.
Published: (2021-04-01)